High Potency APIs Market/HPAPI Market

High Potency APIs Market/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region - Global forecast to 2027

Report Code: PH 4897 May, 2022, by marketsandmarkets.com

[282 Pages Report] The global HPAPI market is projected to reach USD 39.6 billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine.

High Potency APIs/HPAPI Market

To know about the assumptions considered for the study, Request for Free Sample Report

Impact of Covid-19 on HPAPI Market

During the COVID 19 pandemic, the HPAPI market was adversely affected. COVID 19 primarily affected the supply chain of the HPAPI market. Since Southeast Asia (specifically China and India) is the hub for producing API, the market was severely hampered as the impact of COVID-19 increased in this region. The growth of the HPPAI market has been significantly hampered by the economic situation triggered by the COVID-19 pandemic in 2020. Players are expected to benefit as the proportion of firms outsourcing to locations with low-cost production technology is escalating at a rapid pace. The importance of active pharmaceutical ingredient manufacturers in the pharmaceutical industry is evolving in response to new demands from customers and growing pressures from global competitors, thus, transforming the HPAPI market into an attractive area for investment. Firms with existing HPAPI capabilities are busily expanding their facilities, while many without having sought to acquire existing businesses or add HPAPI capacity to their mainstream. Many manufacturers across many territories and levels of experience are making a considerable number of investments in HPAPI capabilities and are getting acquainted with facing numerous challenges in terms of barriers to entry, regulatory requirements, sizeable investments, and expertise associated with APIs & HPAPIs development.

CDMOs with integrated capabilities in HPAPIs will have a competitive edge over others as they can add value to companies outsourcing these products in terms of cost and timelines. Also, dozens of manufacturers are investing in the space, not just the largest players, suggesting that emerging firms see an opportunity for accelerated growth from new product introductions and will, accordingly, compete aggressively. The rising trend toward outsourcing for HPAPI production along with the developments in favorable regulatory frameworks are the major factors expected to bolster the growth of the global HPAPI market. The escalation in the HPAPI drug market is subjected to a variety of aspects such as the diversification of pharmaceutical manufacturers towards precision medicines such as HPAPI, increasing demand for oncology drugs & antibody-drug conjugates, and advancements in HPAPI manufacturing technologies. Other factors such as the growth in the geriatric population; increase in disposable income; the prevalence of chronic, lifestyle, and age-related diseases,; alongside government efforts to reform healthcare and its initiatives to encourage the adoption of generics are also the key growth drivers in this segment. The pharmaceutical sector of HPAPI is highly fragmented, oncology being the largest and fastest-growing segment among all. HPAPIs are used as antibody-drug conjugates (ADCs), which in combination with monoclonal antibodies & biologically active drugs, are a very important and effective treatment for cancer.

HPAPI Market Dynamics

Driver: Increasing demand for oncology drugs

The rising demand for oncology drugs is anticipated to create a wide scope of opportunities in the global HPAPI market. HPAPIs are extremely effective pharmacologically active ingredients, which offer significant efficiency in the action and efficiency even at low doses. The growing incidence and prevalence of cancer, there is a growth in demand for more potent cancer therapeutics, including HPAPIs. To cater to the growing demand, various pharmaceutical companies such as Pfizer, Sanofi, F. Hoffmann-La Roche, and others are increasingly making efforts toward building pipelines for novel cancer therapeutics.

Opportunity: Growing opportunities for CMOs and CDMOs

A comprehensive HPAPI manufacturing facility requires extensive planning, the use of risk management and assessment tools, and a mechanism to determine which compounds are suitable for manufacturing in each facility. The production of such compounds poses hazards and risks to workers and the environment. Pharmaceutical manufacturers also need to have the capacity for the safe production, storage, and transport of a growing range of potent compounds. This makes it evident that implementing a successful HPAPI manufacturing strategy requires significant time and investment. Hence, various sponsor companies prefer going to CMOs and CDMOs for assistance with the development, manufacturing, and distribution of HPAPIs and their formulated drug products, as many of these companies have the necessary equipment.

Challenge: Need for appropriate process designs

Process designs are one of the most vital requirements for HPAPI production operations. Most HPAPI and ADC drug payloads need to be produced in small clinical and commercial quantities. However, the production of gram scale GMP APIs and payloads is challenging. Maintaining containment control when using flexible and small equipment, including glass equipment, is a definite challenge and requires an approach that is tailored for each process and unit operation. It is also important to maintain appropriate process designs at the developmental scale to ensure that the process fits the equipment and capabilities of the facility upon scale-up. Furthermore, industry-wide, there is an ambiguity regarding the classification of HPAPIs. Different pharmaceutical companies often have proprietary systems, and the classification of new APIs is unknown due to a lack of data. These issues can be mitigated with appropriate process designs and containment controls, which most companies lack. All these factors collectively are likely to present a significant challenge for players in the HPAPI market.

Restraints: High risk of cross-contamination

The biggest risks associated with HPAPI manufacturing is cross-contamination (detrimental contamination of a product with a different product). Growing pressure on the pharmaceutical industry to control costs and to make biopharmaceuticals economical to the consumers are major factors compelling the industry to utilize effective and efficient multi-product and multi-purpose facilities to the greatest extent possible. Along with high potency, HPAPIs often exhibit high cytotoxicity, therefore efforts to prevent cross-contamination are essential to a safe manufacturing process which guarantees the wellbeing of employees, the environment, and the patient.

The report divide the market into type, type of synthesis, type of manufacturer, by therapeutic application and region. Based on type, the market is divided into generic HPAPI and innovative HPAPI. In 2021, the innovative segment will grow largest share in the market. Some Factors contributing to the market growth can be increasing investments in R&D to drive the market growth of this segment.

Based on type of synthesis, the market is divided into biotech HPAPI and synthetic HPAPI segment. The synthetic HPAPI segment to command the largest share in 2021. Increasing number of new APIs, approvals and ease of production are driving the growth of synthetic segment.

Based on the type of manufacturer, the market is segmented into merchant HPAPI manufacturers and captive HPAPI manufacturers. In 2021 the captive HPAPI manufacturers market to account for largest share of market. Factors such as companies in-house manufacturing facilities for economic benefits to drive the segment.

Based on therapeutic application, the market is segmented into oncology, glaucoma, hormonal imbalance, and other therapeutic applications. The oncology segment to dominate the market during 2021. The growing prevalence of cancer and launch of new target therapies are the key factors for the growth in the segment.

By Region, the HPAPI market is segmented into North America, Europe, Asia, and the rest of World (RoW). North America is expected to dominate the market in 2021. Factors such as growing oncology sector, prevlance and incidence of chronic diseases and lifestyle diseases to drive the market segment in North America.

High Potency APIs/HPAPI Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

The major players in the HPAPI market include Pfizer, Inc. (US), F. Hoffmann-La Roche (Switzerland), Sanofi (France), Bristol-Myers Squibb Company (US), Bayer AG (Germany), Novartis International AG (Switzerland), Boehringer Ingelheim International GmbH. (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), Merck & Co., Inc. (US), AbbVie (US), and Viatris Inc. (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

HPAPI Market :2022–2027

Base year considered

HPAPI Research Spending Market:2021

Forecast period

HPAPI Market :2022–2027

Forecast units

Values (USD Million)

Segments covered

HPAPI Market—Type, Type of Synthesis, Type of manufacturers, Therapeutic application, and Region

Geographies covered

HPAPI Market: North America (US & Canada), Europe (UK, Germany, France, Italy, Spain and RoE) Asia (China, Japan, India, RoA), and RoW

Companies covered

Pfizer, Inc. (US), F. Hoffmann-La Roche (Switzerland), Sanofi (France), Bristol-Myers Squibb Company (US), Bayer AG (Germany), Novartis International AG (Switzerland), Boehringer Ingelheim International GmbH. (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), Merck & Co., Inc. (US), AbbVie (US), and Viatris Inc. (US).

Based on type, the HPAPI market is segmented as follows:

  • Innovative API Market
  • Generic API Market

Based on type of Synthesis, the HPAPI market is segmented as follows:

  • Synthetic API Market
  • Biotech API Market

Based on type of manufacturers, the HPAPI market is segmented as follows:

  • Captive API Market
  • Merchant API Market

Based on therapeutic application, the HPAPI market is segmented as follows:

  • Oncology
  • Hormonal Imbalance
  • Glaucoma
  • Other therapeutic applications

Based on region, the HPAPI market is segmented as follows:

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • ROE
  • Asia
    • Japan
    • China
    • India
    • ROA
  • Rest of the World (RoW)

Recent Developments:

  • In 2022, Pfizer acquired Arena Pharmaceuticals. The deal will benefit in bringing the pipeline of Arena Pharmaceuticals to the company’s Inflammation and Immunology Therapeutic Area, helping in the further developments to change the lives of those with immuno-inflammatory diseases.
  • In 2021, Sandoz, a Novartis division, had successfully completed the acquisition of GSK’s Cephalosporin Antibiotics business. Through this transaction, Sandoz had acquired the rights to three established brands (Zinnat, Zinacef, and Fortum) in more than 100 markets, further reinforcing its leading global position in antibiotics.
  • In 2020, La Roche collaborated with Atea Pharmaceuticals to develop a potential oral treatment for the COVID-19 patients.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 30)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE
           1.3.1 MARKETS COVERED
                    FIGURE 1 HPAPI MARKET: GEOGRAPHIC SCOPE
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 SUMMARY OF CHANGES
    1.7 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 35)
    FIGURE 2 RESEARCH DESIGN
    2.1 SECONDARY DATA
           2.1.1 SECONDARY SOURCES
    2.2 PRIMARY DATA
           FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: HPAPI MARKET
           2.2.1 KEY DATA FROM PRIMARY SOURCES
           2.2.2 PRIMARY INSIGHTS
    2.3 MARKET SIZE ESTIMATION
           FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
           FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
    2.4 MARKET GROWTH RATE PROJECTIONS
           FIGURE 6 HPAPI MARKET: CAGR PROJECTIONS
    2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 7 DATA TRIANGULATION
    2.6 RESEARCH ASSUMPTIONS
    2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 44)
    FIGURE 8 HPAPI MARKET, BY TYPE, 2021 VS. 2027
    FIGURE 9 HPAPI MARKET, BY TYPE OF MANUFACTURER, 2021 VS. 2027
    FIGURE 10 HPAPI MARKET, BY TYPE OF SYNTHESIS, 2021 VS. 2027
    FIGURE 11 HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2021 VS. 2027
    FIGURE 12 GEOGRAPHIC SNAPSHOT OF HPAPI MARKET (2022–2027)

4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 HPAPI: MARKET OVERVIEW
          FIGURE 13 INCREASING DEMAND FOR ONCOLOGY DRUGS AND ANTIBODY-DRUG CONJUGATES TO DRIVE MARKET GROWTH
    4.2 HPAPI MARKET, BY TYPE, (2021 VS. 2027)
          FIGURE 14 INNOVATIVE HPAPIS TO DOMINATE THE GLOBAL MARKET IN 2027
    4.3 HPAPI MARKET, BY TYPE OF SYNTHESIS, (2021 VS. 2027)
          FIGURE 15 SYNTHETIC HPAPIS TO DOMINATE MARKET SHARE IN 2021
    4.4 HPAPI MARKET BY THERAPEUTIC AREA (2021–2027)
          FIGURE 16 ONCOLOGY SEGMENT TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
    4.5 GEOGRAPHICAL SNAPSHOT OF HPAPI MARKET
          FIGURE 17 CHINA & INDIA TO REGISTER HIGH GROWTH RATES DURING 2022–2027

5 MARKET OVERVIEW (Page No. - 53)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 18 HPPAI MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing demand for oncology drugs
                                TABLE 1 PIPELINE OF ONCOLOGY DRUGS (2021)
                    5.2.1.2 Growing demand for antibody-drug conjugates
                    5.2.1.3 Increasing focus of leading pharmaceutical companies on HPAPIs
                    5.2.1.4 Advancements in HPAPI manufacturing technologies
                    5.2.1.5 Growing focus on precision medicine
           5.2.2 RESTRAINTS
                    5.2.2.1 Increasing requirement of large investments for employee safety
                    5.2.2.2 Discrepancies in HPAPI banding systems
                    5.2.2.3 Rising number of uncertainties associated with products
                    5.2.2.4 High risk of cross-contamination
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing opportunities for CMOs and CDMOs
                    5.2.3.2 Increasing opportunities for companies in emerging markets
           5.2.4 CHALLENGES
                    5.2.4.1 Need for appropriate process designs
                    5.2.4.2 Constant evolution of industry standards and technologies
    5.3 IMPACT OF COVID-19 ON HPAPI MARKET
    5.4 TARIFF AND REGULATORY LANDSCAPE
           5.4.1 HANDLING HPAPI
           5.4.2 THIRD PARTY CERTIFICATION
           5.4.3 CONTAINMENT STRATEGIES
           5.4.4 CHALLENGES
    5.5 PORTER’S FIVE FORCES ANALYSIS
          TABLE 2 HPAPI MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.5.1 THREAT OF NEW ENTRANTS
           5.5.2 THREAT OF SUBSTITUTES
           5.5.3 BARGAINING POWER OF SUPPLIERS
           5.5.4 BARGAINING POWER OF BUYERS
           5.5.5 DEGREE OF COMPETITION
    5.6 TECHNOLOGY ANALYSIS
           5.6.1 HANDLING POTENT COMPOUNDS
           5.6.2 CONTROLS
           5.6.3 SAFETY ASSESSMENT AND STANDARD OPERATING PROCEDURES
           5.6.4 DEDICATED EQUIPMENT AND SYSTEMS
           5.6.5 EXPERTISE AND TRAINING
           5.6.6 COMBUSTIBLE DUST HANDLING
           5.6.7 SUITABLE PERSONAL PROTECTIVE EQUIPMENT
    5.7 SUPPLY CHAIN ANALYSIS
           FIGURE 19 HPAPI MARKET: SUPPLY CHAIN ANALYSIS
    5.8 PRICING ANALYSIS
          TABLE 3 SELLING PRICE OF HPAPI PRODUCTS BY TOP PLAYERS
    5.9 KEY CONFERENCES & EVENTS IN 2022–2023
          TABLE 4 HPAPI MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
           5.10.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
                     FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS OF HPAPI
           5.10.2 BUYING CRITERIA FOR HPAPI
                     FIGURE 21 KEY BUYING CRITERIA FOR END USERS

6 HPAPI CLASSIFICATION AND OVERVIEW (Page No. - 69)
    6.1 INTRODUCTION
    6.2 HPAPI INGREDIENTS CLASSIFICATION AS PER SAFEBRIDGE CONSULTANTS
          TABLE 5 CATEGORIES OF HPAPIS
          TABLE 6 POTENCY CLASSIFICATION SYSTEM

7 HPAPI MARKET, BY TYPE (Page No. - 72)
    7.1 INTRODUCTION
          FIGURE 22 INNOVATIVE HPAPIS SEGMENT TO DOMINATE HPAPI MARKET
          TABLE 7 HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
    7.2 INNOVATIVE HPAPIS
          TABLE 8 INNOVATIVE HPAPIS MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 9 NORTH AMERICA: INNOVATIVE HPAPIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 10 EUROPE: INNOVATIVE HPAPIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 11 ASIA: INNOVATIVE HPAPIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 GENERIC HPAPIS
          TABLE 12 GENERIC HPAPIS MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 13 NORTH AMERICA: GENERIC HPAPIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 14 EUROPE: GENERIC HPAPIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 15 ASIA: GENERIC HPAPIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

8 HPAPI MARKET, BY TYPE OF SYNTHESIS (Page No. - 79)
    8.1 INTRODUCTION
          FIGURE 23 SYNTHETIC SEGMENT TO DOMINATE MARKET IN 2021
          TABLE 16 HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
    8.2 SYNTHETIC APIS
          TABLE 17 SYNTHETIC APIS MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 18 NORTH AMERICA: SYNTHETIC APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 19 EUROPE: SYNTHETIC APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 20 ASIA: SYNTHETIC APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           8.2.1 SYNTHETIC APIS MARKET, BY TYPE
                    TABLE 21 SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 22 INNOVATIVE SYNTHETIC APIS
                    TABLE 23 INNOVATIVE SYNTHETIC APIS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 24 NORTH AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 25 EUROPE: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 26 ASIA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           8.2.2 GENERIC SYNTHETIC APIS
                    TABLE 27 GENERIC SYNTHETIC APIS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 28 NORTH AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 29 EUROPE: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 30 ASIA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 BIOTECH APIS
          TABLE 31 BIOTECH APIS MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 32 NORTH AMERICA: BIOTECH APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 33 EUROPE: BIOTECH APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 34 ASIA: BIOTECH APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           8.3.1 BIOTECH APIS MARKET, BY TYPE
                    TABLE 35 BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
           8.3.2 INNOVATIVE BIOTECH APIS
                    TABLE 36 INNOVATIVE BIOTECH APIS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 37 NORTH AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 38 EUROPE: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 39 ASIA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           8.3.3 BIOSIMILARS
                    TABLE 40 BIOSIMILARS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 41 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 42 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 43 ASIA: BIOSIMILARS INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           8.3.4 BIOTECH APIS MARKET, BY PRODUCT
                    TABLE 44 BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
           8.3.5 MONOCLONAL ANTIBODIES
                    TABLE 45 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2020–2027 (USD MILLION)
           8.3.6 VACCINES
                    TABLE 46 VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION)
           8.3.7 RECOMBINANT PROTEINS
                    TABLE 47 RECOMBINANT PROTEINS MARKET, BY REGION, 2020–2027 (USD MILLION)

9 HPAPI MARKET, BY TYPE OF MANUFACTURER (Page No. - 99)
    9.1 INTRODUCTION
          FIGURE 24 CAPTIVE HPAPI MANUFACTURERS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2021
          TABLE 48 HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
    9.2 CAPTIVE API MANUFACTURERS
          TABLE 49 CAPTIVE API MANUFACTURERS MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 50 NORTH AMERICA: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
          TABLE 51 EUROPE: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 52 ASIA: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 MERCHANT API MANUFACTURERS
          TABLE 53 MERCHANT API MANUFACTURERS MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 54 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
          TABLE 55 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 56 ASIA: MERCHANT API MANUFACTURERS MARKET,  BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.1 MERCHANT API MANUFACTURERS MARKET BY TYPE
                    TABLE 57 MERCHANT API MANUFACTURERS MARKET BY TYPE, 2020–2027, (USD MILLION)
           9.3.2 INNOVATIVE MERCHANT API MANUFACTURERS
                    TABLE 58 INNOVATIVE MERCHANT API MANUFACTURERS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 59 NORTH AMERICA: INNOVATIVE MERCHANT API MANUFACTURERS MARKET,  BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 60 EUROPE: INNOVATIVE MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 61 ASIA: INNOVATIVE MERCHANT API MANUFACTURERS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
           9.3.3 GENERIC MERCHANT API MANUFACTURERS
                    TABLE 62 GENERIC MERCHANT API MANUFACTURERS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 63 NORTH AMERICA: GENERIC MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 64 EUROPE: GENERIC MERCHANT API MANUFACTURERS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
                    TABLE 65 ASIA: GENERIC MERCHANT API MANUFACTURERS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
           9.3.4 MERCHANT API MANUFACTURERS MARKET,  BY TYPE OF SYNTHESIS
                    TABLE 66 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 , (USD MILLION)
           9.3.5 SYNTHETIC API MANUFACTURERS
                    TABLE 67 SYNTHETIC API MANUFACTURERS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 68 NORTH AMERICA: SYNTHETIC API MANUFACTURERS MARKET,  BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 69 EUROPE: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 70 ASIA: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.6 BIOTECH API MANUFACTURERS
                    TABLE 71 BIOTECH API MANUFACTURERS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 72 NORTH AMERICA: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 73 EUROPE: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 74 ASIA: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

10 HPAPI MARKET, BY THERAPEUTIC APPLICATION (Page No. - 116)
     10.1 INTRODUCTION
             FIGURE 25 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
             TABLE 75 HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
     10.2 ONCOLOGY
             TABLE 76 HPAPI MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION)
             TABLE 77 NORTH AMERICA: HPAPI MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 78 EUROPE: HPAPI MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 79 ASIA: HPAPI MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
     10.3 HORMONAL IMBALANCE
             TABLE 80 HPAPI MARKET FOR HORMONAL IMBALANCE, BY REGION, 2020–2027 (USD MILLION)
             TABLE 81 NORTH AMERICA: HPAPI MARKET FOR HORMONAL IMBALANCE, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 82 EUROPE: HPAPI MARKET FOR HORMONAL IMBALANCE, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 83 ASIA: HPAPI MARKET FOR HORMONAL IMBALANCE, BY COUNTRY, 2020–2027 (USD MILLION)
     10.4 GLAUCOMA
             TABLE 84 HPAPI MARKET FOR GLAUCOMA,  BY REGION, 2020–2027 (USD MILLION)
             TABLE 85 NORTH AMERICA: HPAPI MARKET FOR GLAUCOMA, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 86 EUROPE: HPAPI MARKET FOR GLAUCOMA, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 87 ASIA: HPAPI MARKET FOR GLAUCOMA, BY COUNTRY, 2020–2027 (USD MILLION)
     10.5 OTHER THERAPEUTIC APPLICATIONS
             TABLE 88 HPAPI MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION,  2020–2027 (USD MILLION)
             TABLE 89 NORTH AMERICA: HPAPI MARKET FOR OTHER THERAPEUTIC APPLICATIONS,  BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 90 EUROPE: HPAPI MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 91 ASIA: HPAPI MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY,  2020–2027 (USD MILLION)

11 HPAPI MARKET, BY REGION (Page No. - 128)
     11.1 INTRODUCTION
             TABLE 92 HPAPI MARKET, BY REGION, 2020–2027 (USD MILLION)
     11.2 NORTH AMERICA
             FIGURE 26 NORTH AMERICA: HPAPI MARKET SNAPSHOT
             TABLE 93 NORTH AMERICA: HPAPI MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 94 NORTH AMERICA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 95 NORTH AMERICA: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
             TABLE 96 NORTH AMERICA: MERCHANT APIS MANUFACTURERS MARKET, BY TYPE,  2020–2027 (USD MILLION)
             TABLE 97 NORTH AMERICA: MERCHANT APIS MANUFACTURERS MARKET,  BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
             TABLE 98 NORTH AMERICA: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
             TABLE 99 NORTH AMERICA: SYNTHETIC APIS INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 100 NORTH AMERICA: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 101 NORTH AMERICA: BIOTECH HPAPI MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 102 NORTH AMERICA: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.2.1 US
                        11.2.1.1 Increasing Investments in cancer research to drive market growth
                                      TABLE 103 US: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 104 US: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                                      TABLE 105 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 106 US: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                                      TABLE 107 US: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                                      TABLE 108 US: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 109 US: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION
                                      TABLE 110 US: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 111 US: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 The rising prevalence of cancer to drive market growth
                                      TABLE 112 CANADA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 113 CANADA: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                                      TABLE 114 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 115 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                                      TABLE 116 CANADA: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                                      TABLE 117 CANADA: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 118 CANADA: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 119 CANADA: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 120 CANADA: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
     11.3 EUROPE
             FIGURE 27 EUROPE: HPAPI MARKET SNAPSHOT
             TABLE 121 EUROPE: HPAPI MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 122 EUROPE: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 123 EUROPE: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
             TABLE 124 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 125 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
             TABLE 126 EUROPE: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
             TABLE 127 EUROPE: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 128 EUROPE: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 129 EUROPE: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 130 EUROPE: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 The strong focus on biotech and medical research to drive market growth
                                      TABLE 131 GERMANY: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 132 GERMANY: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                                      TABLE 133 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 134 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                                      TABLE 135 GERMANY: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                                      TABLE 136 GERMANY: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 137 GERMANY: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 138 GERMANY: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 139 GERMANY: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.3.2 FRANCE
                        11.3.2.1 The presence of many pharmaceutical companies coupled with the growing demand for novel cancer therapies to drive market growth
                                      TABLE 140 FRANCE: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 141 FRANCE: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                                      TABLE 142 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 143 FRANCE: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                                      TABLE 144 FRANCE: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                                      TABLE 145 FRANCE: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 146 FRANCE: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 147 FRANCE: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 148 FRANCE: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Increasing in the demand for cancer therapies  to drive market growth
                                      TABLE 149 UK: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 150 UK: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                                      TABLE 151 UK: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 152 UK: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                                      TABLE 153 UK: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                                      TABLE 154 UK: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 155 UK: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 156 UK: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 157 UK: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Robust generic API production capacities to drive the market growth
                                      TABLE 158 ITALY: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 159 ITALY: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                                      TABLE 160 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 161 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                                      TABLE 162 ITALY: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                                      TABLE 163 ITALY: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 164 ITALY: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 165 ITALY: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 166 ITALY: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Developments in the ADC segment to drive market growth
                                      TABLE 167 SPAIN: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 168 SPAIN: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                                      TABLE 169 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 170 SPAIN: MERCHANT MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                                      TABLE 171 SPAIN: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                                      TABLE 172 SPAIN: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 173 SPAIN: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 174 SPAIN: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 175 SPAIN: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 176 REST OF EUROPE: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 177 REST OF EUROPE: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                        TABLE 178 REST OF EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,  2020–2027 (USD MILLION)
                        TABLE 179 REST OF EUROPE: MERCHANT MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                        TABLE 180 REST OF EUROPE: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                        TABLE 181 REST OF EUROPE: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 182 REST OF EUROPE: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 183 REST OF EUROPE: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 184 REST OF EUROPE: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
     11.4 ASIA
             FIGURE 28 ASIA: HPAPI MARKET SNAPSHOT
             TABLE 185 ASIA: HPAPI MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 186 ASIA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 187 ASIA: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
             TABLE 188 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 189 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
             TABLE 190 ASIA: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
             TABLE 191 ASIA: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 192 ASIA: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 193 ASIA: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 194 ASIA: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.4.1 JAPAN
                        11.4.1.1 Investments in the development of ADC products to drive market growth
                                      TABLE 195 JAPAN: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 196 JAPAN: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                                      TABLE 197 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 198 JAPAN: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                                      TABLE 199 JAPAN: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                                      TABLE 200 JAPAN: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 201 JAPAN: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 202 JAPAN: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 203 JAPAN: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.4.2 CHINA
                        11.4.2.1 Low labor costs, presence of well-equipped manufacturing plants to drive market growth
                                      TABLE 204 CHINA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 205 CHINA: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                                      TABLE 206 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 207 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                                      TABLE 208 CHINA: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                                      TABLE 209 CHINA: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 210 CHINA: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 211 CHINA: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 212 CHINA: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Increasing Investments in Oncology to drive market growth
                                      TABLE 213 INDIA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 214 INDIA: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                                      TABLE 215 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 216 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                                      TABLE 217 INDIA: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                                      TABLE 218 INDIA: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 219 INDIA: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 220 INDIA: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 221 INDIA: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
             11.4.4 REST OF ASIA
                        TABLE 222 REST OF ASIA: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 223 REST OF ASIA: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
                        TABLE 224 REST OF ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 225 REST OF ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
                        TABLE 226 REST OF ASIA: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
                        TABLE 227 REST OF ASIA: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 228 REST OF ASIA: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 229 REST OF ASIA: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 230 REST OF ASIA: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
     11.5 REST OF THE WORLD
             FIGURE 29 REST OF THE WORLD: HPAPI MARKET SNAPSHOT
             TABLE 231 ROW: HPAPI MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 232 ROW: HPAPI MARKET, BY TYPE OF MANUFACTURER, 2020–2027 (USD MILLION)
             TABLE 233 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 234 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,  2020–2027 (USD MILLION)
             TABLE 235 ROW: HPAPI MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD MILLION)
             TABLE 236 ROW: SYNTHETIC APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 237 ROW: BIOTECH APIS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 238 ROW: BIOTECH APIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 239 ROW: HPAPI MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 210)
     12.1 OVERVIEW
     12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
             FIGURE 30 KEY DEVELOPMENTS IN HPAPI MARKET, 2019–2022
     12.3 MARKET SHARE ANALYSIS
             FIGURE 31 HPAPI MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021
             TABLE 240 HPAPI MARKET: DEGREE OF COMPETITION
     12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
             FIGURE 32 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN HPAPI MARKET, 2019–2021
     12.5 COMPANY EVALUATION QUADRANT
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
                        FIGURE 33 HPAPI MARKET: COMPANY EVALUATION QUADRANT
     12.6 FOOTPRINT OF COMPANIES
             TABLE 241 PORTFOLIO ANALYSIS BY TYPE OF SYNTHESIS: HPAPI MARKET (2021)
             TABLE 242 PORTFOLIO ANALYSIS BY TYPE OF MANUFACTURER: HPAPI MARKET (2021)
             TABLE 243 PORTFOLIO ANALYSIS BY TYPE OF THERAPEUTIC APPLICATIONS: HPAPI MARKET (2021)
     12.7 REGIONAL FOOTPRINT
             TABLE 244 REGIONAL FOOTPRINT OF COMPANIES: HPAPI MARKET (2021)
     12.8 COMPETITIVE SCENARIO
             TABLE 245 PRODUCT LAUNCHES
             TABLE 246 DEALS

13 COMPANY PROFILES (Page No. - 220)
     13.1 MAJOR PLAYERS
(Business overview, Products offered, Recent Developments, MNM view)*
             13.1.1 PFIZER INC.
                        TABLE 247 PFIZER INC.: BUSINESS OVERVIEW
                        FIGURE 34 PFIZER INC.: COMPANY SNAPSHOT (2021)
             13.1.2 NOVARTIS INTERNATIONAL AG
                        TABLE 248 NOVARTIS INTERNATIONAL AG: BUSINESS OVERVIEW
                        FIGURE 35 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2021)
             13.1.3 SANOFI
                        TABLE 249 SANOFI: BUSINESS OVERVIEW
                        FIGURE 36 SANOFI: COMPANY SNAPSHOT (2021)
             13.1.4 F. HOFFMANN-LA ROCHE
                        TABLE 250 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
                        FIGURE 37 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)
             13.1.5 BRISTOL-MYERS SQUIBB COMPANY
                        TABLE 251 BRISTOL-MYERS SQUIBB COMPANY: BUSINESS OVERVIEW
                        FIGURE 38 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2021)
             13.1.6 BOEHRINGER-INGELHEIM
                        TABLE 252 BOEHRINGER-INGELHEIM: BUSINESS OVERVIEW
                        FIGURE 39 BOEHRINGER-INGELHEIM: COMPANY SNAPSHOT (2021)
             13.1.7 TEVA PHARMACEUTICAL INDUSTRY LTD.
                        TABLE 253 TEVA PHARMACEUTICAL INDUSTRY LTD.: BUSINESS OVERVIEW
                        FIGURE 40 TEVA PHARMACEUTICAL INDUSTRY LTD.: COMPANY SNAPSHOT (2021)
             13.1.8 ELI LILY AND COMPANY
                        TABLE 254 ELI LILY AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 41 ELI LILY AND COMPANY: COMPANY SNAPSHOT (2021)
             13.1.9 MERCK & CO., INC.
                        TABLE 255 MERCK & CO., INC.: BUSINESS OVERVIEW
                        FIGURE 42 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
             13.1.10 ABBVIE INC.
                        TABLE 256 ABBVIE INC.: BUSINESS OVERVIEW
                        FIGURE 43 ABBVIE INC.: COMPANY SNAPSHOT (2021)
             13.1.11 VIATRIS INC.
                        TABLE 257 VIATRIS INC.: BUSINESS OVERVIEW
                        FIGURE 44 VIATRIS INC.: COMPANY SNAPSHOT (2021)
             13.1.12 BAYER
                        TABLE 258 BAYER AG: BUSINESS OVERVIEW
                        FIGURE 45 BAYER AG: COMPANY SNAPSHOT (2021)

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

14 APPENDIX (Page No. - 276)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This research study involved the extensive use of secondary sources; directories; databases such as D&B, Bloomberg Business, and Factiva; white papers; annual reports; company house documents; and SEC filings of companies. Secondary research was mainly used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the HPAPI market.

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary research was also used to obtain key information about the market classification and segmentation according to industry trends, regional markets, and developments.

Secondary Data

In the secondary research process, various sources were referred to identify and collect useful information for the study. These sources included annual reports, press releases, investor presentations of companies, white papers, certified publications, articles from recognized authors, gold standard and silver standard websites, directories, and databases.

Secondary research was mainly used to obtain key information about the industry’s value chain, market classification, and segmentation according to the industry trends to the bottom-most level, geographical markets, and key developments from both market and technology oriented perspectives.

Primary Sources

Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the HPAPI market. Primary sources from the demand side included purchasing officers in pharmaceutical and biotechnology companies.

High Potency APIs/HPAPI Market Size, and Share

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the sizes of the market and various other dependent submarkets. The research methodology used to estimate the market size includes the following details:

  • The key players in the market were identified through secondary research, and their market contributions were determined through primary and secondary research.
  • This entire procedure included the study of the annual and financial reports of the top market players and extensive interviews for the key insights from industry leaders.
  • All percentage shares, splits, and breakdowns were determined by secondary sources and verified through primary sources.
  • All possible parameters affecting the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to reach the final quantitative and qualitative data.
  • The data mentioned above is consolidated and added with detailed inputs and analyses from MarketsandMarkets and presented in this report.

Data Triangulation

After arriving at the overall market size, the total market was split into several segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all the segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market was validated using both top-down and bottom-up approaches.

Report Objective

  • To define, describe, and forecast the global high potency active pharmaceutical ingredients (HPAPI) market based on type, the type of manufacturer, the type of synthesis, therapeutic application, and region
  • To provide detailed information about factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to the individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments of North America, Europe, Asia, and the Rest of the World
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as agreements, partnerships, collaborations, and alliances; acquisitions; and R&D activities in the global HPAPI market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs.

The following customization options are available for the report:

  • Additional Company Profiling
  • Company profiles for 5 additional companies.
Report Code
PH 4897
Published ON
May, 2022
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved